Letter to the Editor
mTOR inhibitors in a patient with lupus nephritis; why not?
Inhibidores de mTOR en una paciente con nefritis lúpica ¿Por qué no?
Raquel Berzala,
, Beatriz Agredanob, Marco Gilb, María Galindoc,d,e, Enrique Moralesa,d,e
Corresponding author
a Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain
b Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain
c Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain
d Investigation Institute i+12, Hospital Universitario 12 de Octubre, Madrid, Spain
e Departament of Medicine, Universidad Complutense de Madrid, Madrid, Spain
Read
3226
Timeswas read the article
1338
Total PDF
1888
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 12 | 3 | 15 |
| 2025 6 | 153 | 226 | 379 |
| 2025 5 | 80 | 43 | 123 |
| 2025 4 | 334 | 48 | 382 |
| 2025 3 | 95 | 72 | 167 |
| 2025 2 | 85 | 43 | 128 |
| 2025 1 | 84 | 34 | 118 |
| 2024 12 | 65 | 37 | 102 |
| 2024 11 | 52 | 41 | 93 |
| 2024 10 | 72 | 42 | 114 |
| 2024 9 | 58 | 32 | 90 |
| 2024 8 | 78 | 67 | 145 |
| 2024 7 | 53 | 40 | 93 |
| 2024 6 | 47 | 49 | 96 |
| 2024 5 | 71 | 48 | 119 |
| 2024 4 | 76 | 28 | 104 |
| 2024 3 | 60 | 34 | 94 |
| 2024 2 | 81 | 51 | 132 |
| 2024 1 | 34 | 23 | 57 |
| 2023 12 | 25 | 34 | 59 |
| 2023 11 | 28 | 42 | 70 |
| 2023 10 | 26 | 29 | 55 |
| 2023 9 | 27 | 26 | 53 |
| 2023 8 | 27 | 25 | 52 |
| 2023 7 | 28 | 34 | 62 |
| 2023 6 | 23 | 17 | 40 |
| 2023 5 | 24 | 29 | 53 |
| 2023 4 | 14 | 25 | 39 |
| 2023 3 | 16 | 23 | 39 |
| 2023 2 | 21 | 19 | 40 |
| 2023 1 | 25 | 53 | 78 |
| 2022 12 | 14 | 21 | 35 |
Show all
